Chemical Identity

Stanozolol is a synthetic derivative of Dihydrotestosterone, structurally modified with a fused Pyrazole ring attached to the A-ring of the steroid nucleus. It also carries a 17-alpha methyl group, allowing for oral bioavailability.

Molecular Details

Molecular Formula: C₂₁H₃₂N₂O

Molecular Weight: Approximately 328.5 g/mol

Structure Type: DHT-derived anabolic steroid (pyrazole-modified)

Structural Description

The molecule is based on a dihydrotestosterone backbone, meaning it lacks the double bond between C4 and C5 found in testosterone. A key structural feature is the fusion of a pyrazole ring at the A-ring, replacing the typical 3-keto group seen in most anabolic steroids. Additionally, the presence of a 17-alpha methyl group protects the compound from first-pass liver metabolism, enabling effective oral administration. This combination of modifications significantly alters its interaction with androgen receptors and metabolic stability.

Functional Significance

The structural modifications of Stanozolol influence both its pharmacokinetics and activity profile. The 17-alpha methylation allows the compound to survive oral ingestion, while the pyrazole ring contributes to its anabolic characteristics. As a DHT-derived compound, it does not aromatize into estrogen. Stanozolol is typically associated with a relatively short half-life, requiring more frequent administration compared to long-acting esterified compounds.

Summary

Stanozolol is a structurally unique DHT-derived anabolic compound distinguished by its pyrazole ring and 17-alpha methylation. These modifications enable oral activity and contribute to its stability, making it a well-known compound in both research and performance-related settings.